Literature DB >> 29161764

Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.

M Fernandez-Chas1, M J Curtis1, S A Niederer1.   

Abstract

BACKGROUND AND
PURPOSE: Doxorubicin (DOX) is an effective cancer therapeutic agent but causes therapy-limiting cardiotoxicity. The effects of DOX and its metabolite doxorubicinol (DOXL) on individual channels have been well characterized in isolation. However, it is unknown how the action and interaction of affected channels combine to generate the phenotypic cardiotoxic outcome. We sought to develop an in silico model that links drug effects on channels to action potential duration (APD) and intracellular Ca2+ concentration in order to address this gap in knowledge. EXPERIMENTAL APPROACH: We first propose two methods to obtain, from published values, consensus drug effects on the currents of individual channels, transporters and pumps. Separately, we obtained equivalent values for APD and Ca2+ concentration (the readouts used as surrogates for cardiotoxicity). Once derived, the consensus effects on the currents were incorporated into established biophysical models of the cardiac myocyte and were refined adjusting the sarcoplasmic reticulum Ca2+ leak current (ILeak ) until the consensus effects on APD and Ca2+ dynamics were replicated. Using factorial analysis, we then quantified the relative contribution of each channel to DOX and DOXL cardiotoxicity. KEY
RESULTS: The factorial analysis identified the rapid delayed rectifying K+ current, the L-type Ca2+ current and the sarcoplasmic reticulum ILeak as the targets primarily responsible for the cardiotoxic effects on APD and Ca2+ dynamics. CONCLUSIONS AND IMPLICATIONS: This study provides insight into the mechanisms of DOX-induced cardiotoxicity and a framework for the development of future diagnostic and therapeutic strategies.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29161764      PMCID: PMC5811623          DOI: 10.1111/bph.14104

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  67 in total

Review 1.  Calcium fluxes involved in control of cardiac myocyte contraction.

Authors:  D M Bers
Journal:  Circ Res       Date:  2000-08-18       Impact factor: 17.367

Review 2.  Cardiac cell modelling: observations from the heart of the cardiac physiome project.

Authors:  Martin Fink; Steven A Niederer; Elizabeth M Cherry; Flavio H Fenton; Jussi T Koivumäki; Gunnar Seemann; Rüdiger Thul; Henggui Zhang; Frank B Sachse; Dan Beard; Edmund J Crampin; Nicolas P Smith
Journal:  Prog Biophys Mol Biol       Date:  2010-03-18       Impact factor: 3.667

3.  Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration.

Authors:  C Lengyel; N Iost; L Virág; A Varró; D A Lathrop; J G Papp
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration.

Authors:  J Serrano; C M Palmeira; D W Kuehl; K B Wallace
Journal:  Biochim Biophys Acta       Date:  1999-04-21

Review 5.  Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias?

Authors:  S Rees; M J Curtis
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

6.  Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.

Authors:  P S Mushlin; B J Cusack; R J Boucek; T Andrejuk; X Li; R D Olson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  Abnormal myocardial calcium handling in the early stage of adriamycin cardiomyopathy.

Authors:  V I Kapelko; C P Williams; D E Gutstein; J P Morgan
Journal:  Arch Physiol Biochem       Date:  1996       Impact factor: 4.076

8.  Might adriamycinol contribute to adriamycin-induced cardiotoxicity?

Authors:  M Del Tacca; R Danesi; M Ducci; C Bernardini; A Romanini
Journal:  Pharmacol Res Commun       Date:  1985-11

9.  Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model.

Authors:  D A Dodd; J B Atkinson; R D Olson; S Buck; B J Cusack; S Fleischer; R J Boucek
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.

Authors:  Antonella De Angelis; Elena Piegari; Donato Cappetta; Laura Marino; Amelia Filippelli; Liberato Berrino; João Ferreira-Martins; Hanqiao Zheng; Toru Hosoda; Marcello Rota; Konrad Urbanek; Jan Kajstura; Annarosa Leri; Francesco Rossi; Piero Anversa
Journal:  Circulation       Date:  2009-12-28       Impact factor: 29.690

View more
  14 in total

1.  Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells.

Authors:  Ayuob Aghanejad; Hiwa Babamiri; Khosro Adibkia; Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2018-05-05

2.  Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Haojun Huang; Sanam Shafaattalab; Effimia Christidi; Agnes Maillet; Eric Lin; Kate Huang; Zachary Laksman; Margot K Davis; Glen F Tibbits; Liam R Brunham
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

Review 3.  A short history of the development of mathematical models of cardiac mechanics.

Authors:  Steven A Niederer; Kenneth S Campbell; Stuart G Campbell
Journal:  J Mol Cell Cardiol       Date:  2018-11-29       Impact factor: 5.000

4.  Network integration and modelling of dynamic drug responses at multi-omics levels.

Authors:  Nathalie Selevsek; Florian Caiment; Ramona Nudischer; Hans Gmuender; Irina Agarkova; Francis L Atkinson; Ivo Bachmann; Vanessa Baier; Gal Barel; Chris Bauer; Stefan Boerno; Nicolas Bosc; Olivia Clayton; Henrik Cordes; Sally Deeb; Stefano Gotta; Patrick Guye; Anne Hersey; Fiona M I Hunter; Laura Kunz; Alex Lewalle; Matthias Lienhard; Jort Merken; Jasmine Minguet; Bernardo Oliveira; Carla Pluess; Ugis Sarkans; Yannick Schrooders; Johannes Schuchhardt; Ines Smit; Christoph Thiel; Bernd Timmermann; Marcha Verheijen; Timo Wittenberger; Witold Wolski; Alexandra Zerck; Stephane Heymans; Lars Kuepfer; Adrian Roth; Ralph Schlapbach; Steven Niederer; Ralf Herwig; Jos Kleinjans
Journal:  Commun Biol       Date:  2020-10-15

5.  Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.

Authors:  M Fernandez-Chas; M J Curtis; S A Niederer
Journal:  Br J Pharmacol       Date:  2018-01-23       Impact factor: 8.739

6.  Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity.

Authors:  Vincenzo Quagliariello; Raffaele Vecchione; Carmela Coppola; Chiara Di Cicco; Alberta De Capua; Giovanna Piscopo; Rolando Paciello; Viviana Narciso; Carmen Formisano; Orazio Taglialatela-Scafati; Rosario Vincenzo Iaffaioli; Gerardo Botti; Paolo Antonio Netti; Nicola Maurea
Journal:  Nutrients       Date:  2018-09-14       Impact factor: 5.717

7.  Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems.

Authors:  Jo-Fan Chang; Jui-Ling Hsu; Yi-Hua Sheng; Wohn-Jenn Leu; Chia-Chun Yu; She-Hung Chan; Mei-Ling Chan; Lih-Ching Hsu; Shih-Ping Liu; Jih-Hwa Guh
Journal:  Front Oncol       Date:  2019-01-17       Impact factor: 6.244

8.  Balance of Active, Passive, and Anatomical Cardiac Properties in Doxorubicin-Induced Heart Failure.

Authors:  Alexandre Lewalle; Sander Land; Jort J Merken; Anne Raafs; Pilar Sepúlveda; Stéphane Heymans; Jos Kleinjans; Steven A Niederer
Journal:  Biophys J       Date:  2019-07-29       Impact factor: 4.033

9.  Single-Cell Mechanical Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Testing and Pathophysiological Studies.

Authors:  Nimer Ballan; Naim Shaheen; Gordon M Keller; Lior Gepstein
Journal:  Stem Cell Reports       Date:  2020-08-06       Impact factor: 7.765

10.  Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer.

Authors:  Kevin J Lee; Griffin Wright; Hannah Bryant; Leigh Ann Wiggins; Valeria L Dal Zotto; Michele Schuler; Christopher Malozzi; Michael V Cohen; Natalie R Gassman
Journal:  Int J Mol Sci       Date:  2021-07-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.